Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antipsychotic agents].

J P Olie1, S Ghaoui, F J Bayle

  • 1Centre Hospitalier Sainte-Anne, SHU Secteur 14, Paris.

L'Encephale
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

New antipsychotic medications offer improved efficacy and tolerability for schizophrenia treatment, addressing limitations of older neuroleptics. Research continues to refine their use in psychiatric care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Addictive behaviors: Clinical facts].

Bulletin de l'Academie nationale de medecine·2020
Same author

Balneotherapy Together with a Psychoeducation Program for Benzodiazepine Withdrawal: A Feasibility Study.

Evidence-based complementary and alternative medicine : eCAM·2016
Same author

[ADH/D and impulsiveness: Prevalence of impulse control disorders and other comorbidities, in 81 adults with attention deficit/hyperactivity disorder (ADH/D)].

L'Encephale·2016
Same author

[Controlled drug consumption rooms].

Bulletin de l'Academie nationale de medecine·2014
Same author

[Evaluation of functional remission in schizophrenic disorder. The FROGS Scale].

L'Encephale·2013
Same author

Deficit of cognitive inhibition in depressed elderly: a neurocognitive marker of suicidal risk.

Journal of affective disorders·2012
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Neuroscience

Background:

  • Traditional neuroleptics, discovered in 1952, were classified by sedative, positive, and negative symptom effects in schizophrenia.
  • These older agents frequently cause significant side effects, including extrapyramidal syndrome (EPS), leading to poor patient compliance.
  • Clozapine emerged as a more effective and tolerable option for refractory schizophrenia, particularly for negative symptoms.

Purpose of the Study:

  • To review the evolution and efficacy of newer antipsychotic agents.
  • To analyze the adverse effects and expanding indications of modern antipsychotics.
  • To explore the potential of individualized treatment approaches for psychiatric disorders.

Main Methods:

  • Review of pharmacological and therapeutic differences of neuroleptics.

Related Experiment Videos

  • Analysis of clinical effects on positive and negative symptoms of schizophrenia.
  • Evaluation of side effect profiles, including EPS, akathisia, dystonia, and parkinsonism.

    • Main Results:

    • Newer antipsychotics, like clozapine, risperidone, and olanzapine, show improved efficacy, especially for negative symptoms.
    • These agents often exhibit a dual 5HT2 and D2 receptor antagonist mechanism.
    • Adverse effect profiles are generally better tolerated than older neuroleptics, improving compliance.

    Conclusions:

    • Newer antipsychotics represent a significant advancement in schizophrenia and mood disorder management.
    • Further research is needed to establish definitive treatment guidelines for these agents.
    • Individualized treatment strategies using dimensional analysis may optimize antipsychotic efficacy.